

PCAF-Mediated Acetylation Regulates RAD51 Dynamic Localization on Chromatin during HR Repair

Jiajia Hou^{1a}, Munan Shi^{1a}, Jialu Hong¹, Yuting Liu¹, Xinyi Song¹, Haipeng Rao¹, Ying Ma¹,
Chunchun Huang¹, Zhigang Hu¹, Lingfeng He¹, Zhigang Guo^{1*} and Feiyan Pan^{1*}

¹Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences,
Nanjing Normal University, 1 Wen Yuan Road, Nanjing, 210023, China

^a These authors contributed equally to this manuscript.


* To whom correspondence should be addressed:

guo@nynu.edu.cn or panfeiyang@nynu.edu.cn

Table of Contents

Appendix Figure S1

Page 2-3



Appendix Figure S1 PCAF inhibitor promotes HR

A. Immunoblot of Ubi-RAD51 in anti-His-Ubi immunoprecipitates from HEK293T cells transfected with indicated vectors after treatment with 10 μ M MG132 for 6 h. Asterisks indicate heavy chain.

B. Immunoblot (left) and quantification (right) of RAD51 from HeLa cells pretreated with DMSO and PCAFi at indicated doses (10 μ M, 20 μ M, 40 μ M) for 24 hours. DMSO vs 10 μ M ($P=0.0005$),

DMSO vs 20 μ M ($P<0.0001$), DMSO vs 40 μ M ($P<0.0001$).

C. Immunoblot (left) and quantification (right) of ac-RAD51 in anti-RAD51 immunoprecipitates from HEK293T cells treated with DMSO, PCAFi (40 μ M, 24 h). $P=0.0002$.

D. RAD51 or Ac-RAD51 proteins were used to preform an EMSA as indicated.

E. Immunoblot (left) and quantification (right) of γ H2AX and RAD51 in HeLa cells transfected with the indicated vectors and treated with DMSO or ETO (20 μ M, 2h). EV vs WT ($P=0.0003$), EV vs Δ HAT ($P=0.0218$).

F. Representative immunofluorescence images (left) and quantification (right) of RAD51 (red) and γ H2AX (green) foci in HeLa cells pretreated with DMSO and PCAFi (40 μ M, 24 h), followed by ETO exposure (20 μ M, 2 h), with cell recovered for 4 h. DNA was stained by DAPI (blue). Scale bars, 10 μ m, n=50. X indicated that with the chosen microscopy settings, no signal was obtained. RAD51, ETO- ($P=0.835116$), ETO+ ($P<0.0001$). γ H2AX, ETO- ($P=0.760353$), ETO+ ($P<0.0001$). G. Cell cycle analysis of HeLa cells transfected with PCAF-WT or PCAF- Δ HAT. EV vs WT, G1 ($P=0.000677$), S ($P=0.001023$), G2/M ($P=0.011584$). EV vs Δ HAT, G1 ($P=0.108788$), S ($P=0.899971$), G2/M ($P=0.145449$).

H. Cell survival assay in PCAFi-treated (40 μ M, 24 h) HeLa cells in response to different doses of ETO. 3.3 μ M ($P=0.000378$), 11 μ M ($P=0.000897$), 33 μ M ($P=0.000981$), 100 μ M ($P=0.069194$). All data are represented as mean $\pm$ S.D. of three independent experiments. P values are from student's t tests (B-C, E, G-H) or Mann-Whitney U-test (F). ** $P<0.01$, *** $P<0.001$, ns: not significant.